[AIDS with inaugural Pneumocystis pneumonia pneumonia. Impact of triple antiretroviral therapy].
To evaluate the impact of the advent of triple combination therapy for AIDS on the nature of the first AIDS-definiting event, a retrospective study was conducted in the infectious diseases department of the Croix-Rousse Teaching Hospital in Lyon, France. The 280 patients entered in the AIDS registry of the department between January 1, 1994, and August 31, 1998, were studied. In 1994 and 1995, 33.05% of registry entries were for a first AIDS-defining event. After the introduction of triple combination therapy during the second half of 1996, this proportion increased significantly from 30.1% for the period between January 1, 1994, and June 30, 1996, to 56.7% for the period from July 1, 1996 to August 31, 1998 (P = 0.00003). The proportion of Pneumocystis carinii pneumonia (PCP) occurring as the first AIDS-defining event also rose significantly between these two periods, from 47.5% to 82.1% (P = 0.002). These data indicate that triple combination therapy may be associated with an increase in the proportion of first AIDS-defining events, most notably of inaugural PCP. National data support this possibility. It would be of interest to conduct early screening campaigns for AIDS in order to allow early effective therapy.
Yousfi
M
M
Service des Maladies Infectieuses, Hôpital de Boufarik, Wilaya de Blida, Algérie.
Boibieux
A
A
Bouhour
D
D
Biron
F
F
Chidiac
C
C
Peyramond
D
D
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis*; D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D005602:France; D006784:Hospitals, Teaching; D006801:Humans; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis*; D012042:Registries; D012189:Retrospective Studies
D019380:Anti-HIV Agents
SIDA et pneumocystose (PCP) inaugurale. Impact de la trithérapie antirétrovirale.